Serum level of soluble tumor necrosis factor receptor 2 is associated with the outcome of patients with diffuse large B-cell lymphoma treated with the R-CHOP regimen

Objective.CagA+/vacAs1+/vacAm1+ Helicobacter pyloriupregulates the expression of tumor necrosis factor receptor–associated factor 1 (TRAF1), tumor necrosis factor receptor superfamily member 9 (4-1BB), and B-cell lymphoma-extra large (Bcl-xL) in human gastric epithelial cells. We investigated the correlation betweencagA/vacAs1/vacAm1andTRAF1/4-1BB/Bcl-xLexpression in gastric mucosal tissue of patients with gastric disorders.Methods. We collected gastric mucosa samples from 35 chronic, nonatrophic gastritis (CG) patients, 41 atrophic gastritis patients, 44 intestinal metaplasia with atypical hyperplasia (IM) patients, and 28 gastric carcinoma (Ca) patients. The expression of TRAF1,4-1BB, andBcl-xLwas determined using western blotting. The expression ofcagA, vacAs1, andvacAm1inH. pyloriwas examined with polymerase chain reaction.Results. The expression ofTRAF1,4-1BB, andBcl-xLwas significantly upregulated in IM and Ca patients (P<0.05compared with CG). There were more cases ofcagA+/vacAs1+/vacAm1+ H. pyloriinfection in samples with elevatedTRAF1,4-1BB, orBcl-xLexpression (P<0.05). Additionally, there were a remarkably large number of samples with upregulatedTRAF1/4-1BB/Bcl-xLexpression in cases ofcagA+/vacAs1+/vacAm1+ H. pyloriinfection (44 cases, 67.7%;P<0.05).Conclusions. The pathogenesis of IM and Ca may be promoted bycagA+/vacAs1+/vacAm1+ H. pylori, possibly via upregulatedTRAF1,4-1BB, andBcl-xLin gastric mucosal tissue.

Download Full-text

Mechanism and Treatment of Rituximab Resistance in Diffuse Large Bcell Lymphoma

Current Cancer Drug Targets ◽

10.2174/1568009619666190126125251 ◽

2019 ◽

Vol 19 (9) ◽

pp. 681-687 ◽

Cited By ~ 1

Author(s):

Linqing Zou ◽

Guoqi Song ◽

Siyu Gu ◽

Lingling Kong ◽

Shiqi Sun ◽

...

Keyword(s):

Cell Lymphoma ◽

B Cell Lymphoma ◽

Line Treatment ◽

First Line ◽

Chop Regimen ◽

Non Hodgkin Lymphoma ◽

Subtype B ◽

Large B Cell Lymphoma ◽

Large B Cell ◽

First Line Treatment

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype B non-Hodgkin lymphoma in adults. After rituximab being introduced to treat DLBCL, the current first-line treatment is R-CHOP regimen. This regimen greatly improves patient's prognosis, however, relapsed or refractory cases are commonly seen, mainly due to the resistance to rituximab. Although a large number of experiments have been conducted to investigate rituximab resistance, the exac mechanisms and solutions are still unclear. This review mainly explores the possible mechanisms oft rituximab resistance and current new effective treatments for rituximab resistance in DLBCL.

Download Full-text

Tumor necrosis could reflect advanced disease status in patients with diffuse large B cell lymphoma treated with R-CHOP therapy

Annals of Hematology ◽

10.1007/s00277-016-2822-8 ◽

2016 ◽

Vol 96 (1) ◽

pp. 17-23 ◽

Cited By ~ 8

Author(s):

Moo-Kon Song ◽

Joo-Seop Chung ◽

Dong-Yeop Shin ◽

Sung-Nam Lim ◽

Gyeong-won Lee ◽

...

Keyword(s):

B Cell ◽

Tumor Necrosis ◽

Advanced Disease ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Disease Status ◽

Large B Cell Lymphoma ◽

Large B Cell ◽

Chop Therapy

Download Full-text

Primary anaplastic large B-cell lymphoma in mandible: Long-term complete remission with R-CHOP regimen and involved field radiotherapy

Oral Oncology ◽

10.1016/j.oraloncology.2009.04.002 ◽

2009 ◽

Vol 45 (9) ◽

pp. e113

Author(s):

Pasquale Niscola ◽

Massimiliano Palombi ◽

Malgorzata Monika Trawinska ◽

Laura Scaramucci ◽

Marco Giovannini ◽

...

Keyword(s):

Complete Remission ◽

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Chop Regimen ◽

Large B Cell Lymphoma ◽

Involved Field ◽

Involved Field Radiotherapy ◽

Large B Cell

Download Full-text

Primary Mediastinal Large B-Cell Lymphoma during Pregnancy

Case Reports in Hematology ◽

10.1155/2012/197347 ◽

2012 ◽

Vol 2012 ◽

pp. 1-3 ◽

Cited By ~ 5

Author(s):

Cesar A. Perez ◽

Janki Amin ◽

Luz M. Aguina ◽

Maureen Cioffi-Lavina ◽

Edgardo S. Santos

Keyword(s):

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Intrauterine Pregnancy ◽

Chop Regimen ◽

Early Presentation ◽

Large B Cell Lymphoma ◽

Complex Scenario ◽

Fdg Pet Ct ◽

Large B Cell

Non-Hodgkin’s Lymphoma (NHL) rarely presents during pregnancy and primary mediastinal large B-cell lymphoma (PMLBCL) accounts for approximately 2.5% of patients with NHL. The case of a 22-year-old woman who was diagnosed with Stage IIA PMLBCL during week 13 of her intrauterine pregnancy is described. The staging consisted in computed tomography (CT) of the chest and magnetic resonance imaging (MRI) of the abdomen and pelvis. She was managed with R-CHOP regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) for a total of six cycles and, because of the early presentation during the second trimester, she received the entire chemotherapy course during the pregnancy. She delivered a healthy baby at 34 weeks of pregnancy and a18FDG-PET/CT scan demonstrated complete remission after delivery. After 20 months of follow up she remains with no evidence of disease and her 1-year-old son has shown no developmental delays or physical abnormalities. PMLBCL, although an uncommon subgroup of DLBCL, may present during pregnancy and R-CHOP should be considered as one suitable option in this complex scenario.

Download Full-text